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Abstract
Background Structural brain changes associated with Alzheimer’s disease (AD) can occur decades before the onset of 
symptoms. The Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) score has been suggested to be associated with 
accelerated brain atrophy in middle-aged subjects but the regional specificity of atrophic areas remains to be elucidated.
Methods 3T T1-weighted magnetic resonance imaging scans of 160 cognitively healthy middle-aged participants (mean 
age = 52) in the PREVENT-Dementia cohort, from baseline and from follow-up after 2 years, were examined. Images 
were preprocessed using Computational Anatomy Toolbox 12. Voxel-based morphometry was performed in FSL 6.0.1 to 
identify areas of grey matter (GM) volume differences both cross-sectionally and longitudinally between subjects with high 
and low baseline CAIDE score (CAIDE score was dichotomized at cohort-median). A GM percentage of change map was 
created for each subject for evaluation of atrophy over 2 years. Analyses were adjusted for age, gender, education and total 
intracranial volume.
Results Compared to subjects with CAIDE score ≤ 6 (low risk), subjects with CAIDE score > 6 (high risk) showed lower 
GM volume in the temporal, occipital, and fusiform cortex and lingual gyrus at baseline, and greater percentage of GM 
loss over 2 years in the supramarginal gyrus, angular gyrus, precuneus, lateral occipital cortex, superior parietal lobule and 
cingulate gyrus (corrected P < 0.05).
Conclusion This study demonstrated accelerated GM atrophy concentrated in several AD signature cortical regions in healthy 
middle-aged subjects with high CAIDE scores.
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Introduction
Dementia is characterized by cognitive decline, loss of 
memory and behavioral changes, leading to reduced ability 
to perform daily life activities [1]. By 2040, it is expected 
that the number of people with dementia will increase by 
100% in developed countries and by approximately 300% 
in developing countries and heavily populated regions [2]. 
The most common cause of dementia is Alzheimer’s dis-
ease (AD) [3, 4]. Although AD symptoms usually appear 
after the age of 65, the potential neuropathology and brain 
structural alternations underlying AD might occur dec-
ades before the onset of symptoms [5–8]. Furthermore, 
exposure to many risk factors at middle age is associated 
with an increased risk of developing AD later in life [9]. 
Identification of AD structural biomarkers in middle-aged 
subjects at risk of future AD could, therefore, be an impor-
tant step towards early diagnosis and interventions.
Cardiovascular risk factors are well-known risk factors 
for AD and are associated with brain volume changes com-
monly connected with AD [10–13]. Cross-sectional stud-
ies have found associations between cardiovascular risk 
factors (e.g., hypertension, obesity, high cholesterol) and 
decreases in total grey matter (GM) volume, hippocampal 
volume and cortical thickness [11–13]. The Cardiovascu-
lar Risk Factors, Aging and Dementia (CAIDE) score is a 
midlife dementia risk score calculated based on the pop-
ulation-based CAIDE study [14]. Some previous studies 
have demonstrated the association of CAIDE score with 
global brain volume and cognition. For example, a longi-
tudinal study in cognitively healthy older people with a 
mean age of 70 years has shown that higher CAIDE scores 
were associated with lower total GM volume, lower corti-
cal thickness, and worse cognition [11]. A cross-sectional 
study in healthy middle-aged subjects has demonstrated 
that higher CAIDE score was associated with poorer visual 
association learning and lower brain volume [15]. There 
has, however, been limited longitudinal research in cogni-
tively healthy middle-aged people linking CAIDE score to 
longitudinal brain volume changes. A recently published 
longitudinal study in middle-aged subjects (aged 40–59) 
of the PREVENT-Dementia cohort has shown that having 
a midlife CAIDE score > 6 was associated with greater 
whole brain atrophy rate over 2 years [16]. However, the 
specific brain structures responsible for the increased brain 
atrophy with increased midlife CAIDE score are yet to be 
explored. This is important to determine as it might con-
tribute to a better understanding of early brain structural 
atrophy underlying AD and provide specific targets for 
potential early interventions.
Hence, to address the current literature gap in the 
regional specificity of atrophic areas associated with 
dementia risk score in middle-aged people, the primary 
aims of this present study are to use voxel-based morpho-
metry (VBM) to examine the specific brain regions with 
increased atrophy associated with higher CAIDE score and 




This study examined participants of the PREVENT-Demen-
tia cohort study (West London site), an ongoing multi-site 
longitudinal study in the UK and Ireland recruiting cogni-
tively healthy volunteers in the age range of 40–59 [17]. Par-
ticipants were recruited based on dementia family history, 
and their apolipoprotein E (APOE) genotype was recorded 
[17]. All subjects recruited in this cohort were cognitively 
unimpaired and details of baseline cognitive measures have 
been described elsewhere [15]. Magnetic resonance imaging 
(MRI) scans at baseline and at follow-up after 2 years were 
acquired. Participants who had completed both baseline and 
2-year follow-up MRI scans by the time of this study were 
included (n = 168). One subject had missing essential infor-
mation and, therefore, was excluded from image preproc-
essing. Hence, MRI scans of 167 subjects were included in 
image preprocessing.
Dementia risk score
A CAIDE score was calculated for each participant in the 
PREVENT-Dementia cohort. The CAIDE score ranges 
from 0 to 18, calculated by taking into account age, gender, 
education years, systolic blood pressure, body mass index, 
total cholesterol, physical activity, and APOE ε4 carriership 
which is by far a major genetic risk factor for the devel-
opment of sporadic AD [14, 18]. Midlife CAIDE score is 
highly predictive of dementia risk over 20 years and has 
been validated in a large (> 9000 participants) population 
from the US (age range, 40–55 years) [19]. In the present 
study, CAIDE score was treated as a binary variable dichoto-
mized according to the group median (CAIDE score = 6) 
in accordance with the previous methodological approach 
in the research on the same cohort [16]. Baseline CAIDE 
score > 6 will be referred to as CAIDE-high and baseline 
CAIDE score ≤ 6 will be referred to as CAIDE-low in this 
study.
MRI data acquisition and preprocessing
MRI scanning was carried out at the West London Cogni-
tive Disorders Treatment and Research Unit in West London 
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Mental Health Trust, West London, UK using a 3 T SIE-
MENS Magnetom Verio Syngo scanner. A three-dimen-
sional T1-weighted magnetization prepared rapid gradient 
echo (MPRAGE) sequence image was acquired with repeti-
tion time = 2300 ms, echo time = 2.98 ms, FOV = 240 × 256 
 mm2, voxel size = 1.0 × 1.0 × 1.0  mm3, 160 slices with 1 mm 
slice thickness and flip angle = 9°.
The acquired T1-weighted MPRAGE images were pre-
processed using the longitudinal processing stream of the 
Computational Anatomy Toolbox 12 (CAT12) (http://www.
neuro .uni-jena.de/cat/) in Statistical Parametric Mapping 12 
(https ://www.fil.ion.ucl.ac.uk/spm/softw are/spm12 /) based 
on MATLAB version 2019a (R2019a, MathWorks, Natick, 
MA, USA). As part of the longitudinal preprocessing, an 
initial intra-subject rigid registration was applied to realign 
images of all time points and an intra-subject bias correc-
tion was applied. Images were denoised and corrected for 
intensity non-uniformities and segmented into different tis-
sue classes. Images were then spatially normalized using 
Diffeomorphic Anatomical Registration Through Exponen-
tiated Lie Algebra (DARTEL) algorithm and registered to 
the Montreal Neurological Institute (MNI) 152 template. 
The resultant image in MNI space was modulated using the 
Jacobian determinants [20]. Finally, images were spatially 
smoothed with a 8 mm full-width at half maximum (FWHM) 
Gaussian kernel. The absolute and relative volumes of GM, 
white matter (WM), and cerebrospinal fluid (CSF) of the 
whole brain and the total intracranial volume (TIV) were 
calculated based on the segmented maps, as part of the CAT 
12 preprocessing. Relative volume was calculated by divid-
ing absolute volume by TIV, which would control for the 
individual differences in brain sizes. Cortical thickness was 
estimated as part of the preprocessing pipeline in CAT12 
using the projection-based thickness approach [21].
All preprocessed GM images were inspected one-by-
one visually for image quality assurance before further 
analysis. Images with poor quality or issues resulting from 
preprocessing that could not be addressed were excluded. 
Subjects with incidental findings such as meningiomas were 
excluded.
Voxel‑based morphometry
The smoothed, modulated, warped and segmented GM 
images generated from CAT12 preprocessing were used 
for voxel-wise [22] statistical analyses performed in FSL 
6.0.1 (https ://fsl.fmrib .ox.ac.uk/fsl/fslwi ki/FSL). The GM 
images were investigated using voxel-wise general linear 
model (GLM) (https ://fsl.fmrib .ox.ac.uk/fsl/fslwi ki/GLM) 
with permutation nonparametric testing [23] (5000 permuta-
tions). Results were corrected for multiple comparisons in 
FSL by family-wise error (FWE) correction [24]. A FWE-
corrected P value < 0.05 was considered to be statistically 
significant. Brain structures with significant difference 
between the considered groups were identified using the 
Harvard–Oxford Cortical and Subcortical Structural Atlases 
with an overlay of 20% or above of significant clusters with 
a particular structure. Baseline age, gender, education years 
and TIV were included as covariates in GLMs.
To limit the analysis to areas of GM, a GM mask was cre-
ated by binarizing the individual GM images at a threshold 
of 0.1 (i.e., GM areas with GM > 10% were included) using 
MATLAB version 2019a (R2019a, MathWorks, Natick, 
MA, USA). For cross-sectional analyses to investigate any 
baseline difference, voxel-wise two-sample unpaired t-test 
was performed in FSL with a mask including all binarized 
individual baseline GM images to compare the GM volume 
between CAIDE-high and CAIDE-low subjects.
For longitudinal analyses, a percentage of change map 
was created for each subject as in the equation below:
where GM represents the 10% threshold-applied GM image 
(i.e., GM areas with GM > 10% were included). Non-numer-
ical and infinite values were set to 0 in the change map. 
A mask for voxel-wise analysis was created by including 
all areas in the change maps with an absolute threshold of 
0.01 (i.e., areas with absolute values > 0.01 were included) 
to exclude non-numerical and infinite values. Voxel-wise 
two-sample t-test was performed in FSL to compare the 
GM change maps between CAIDE-high and CAIDE-low 
subjects.
To further investigate the regions that showed significant 
differences in longitudinal GM volume change between the 
groups, an “AD signature cortical regions” mask was cre-
ated by including the main cortical regions defined as “AD 
signature” in previous literature (inferior temporal gyrus, 
temporal pole, angular gyrus, superior frontal gyrus, supe-
rior parietal lobule, supramarginal gyrus, precuneus, infe-
rior frontal sulcus) [25] using the Harvard-Oxford Cortical 
Structural Atlases in FSL. The voxels from regions showing 
significant differences in GM volume change between the 
groups that overlap with the AD signature cortical regions 
mask were quantified in FSL.
Statistical analyses
Non-voxel-wise statistical analyses were performed in 
GraphPad Prism 8 (Version 8.3.1 (332)). Comparisons of 
demographic characteristics were performed using chi-
squared tests for categorical variables and Mann–Whitney 
tests for continuous variables. The MRI measurements (i.e., 
relative volumes of GM, WM, and CSF; TIV; and cortical 
thickness) were compared cross-sectionally (i.e., at baseline) 
100 ∗
GMat followup − GMat baseline
GMat baseline
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and longitudinally. The 2-year percentage of change of each 
measurement was calculated using the equation below:
Linear regressions were used with MRI measurements as 
dependent variables in cross-sectional analyses and with 
the 2-year percentage of change of MRI measurements as 
dependent variables in longitudinal analyses. CAIDE score 
as a binary variable was used as an independent variable. 
As APOE ε4 carriership is included in the calculation of 
CAIDE score, post hoc analysis of APOE ε4 carriership 
was performed using it as an independent variable in linear 
regression to investigate whether the effect of CAIDE score 
was driven by APOE ε4 carriership. Age, gender and educa-
tion years were included as covariates in regression analyses.
For all statistical analyses, demographic values and 
CAIDE score at baseline were used. P values < 0.05 were 
considered to be statistically significant.
Results
Characteristics of participants
Out of the 167 subjects with MRI scans preprocessed, 5 
subjects were excluded due to incidental findings: 4 had 
meningioma and 1 had damage due to a brain surgery. Two 
subjects were excluded due to image quality issues in pre-
processing. Hence, 160 was the final analytic sample. Base-
line characteristics of participants are reported in Table 1. 
For those subjects with a family history of dementia, the 
mean age at which the first parent was diagnosed with 
100 ∗
measurement at followup −measurement at baseline
measurement at baseline
dementia was 77 years, and therefore, these subjects were 
estimated at baseline to be approximately 24 years away 
from possible dementia onset based on their parental age 
at diagnosis.
Analyses of whole brain tissues
For the whole sample on average, from baseline to follow-up, 
GM volume decreased by 0.96% ± 1.9%, cortical thickness 
decreased by 0.5% ± 1.0%, WM decreased by 0.12% ± 1.7%, 
and CSF increased by 2.2% ± 5.3%.
Cross-sectionally, CAIDE score was negatively associ-
ated with GM volume and positively associated with CSF 
volume (Table 2). Longitudinally, CAIDE score was asso-
ciated with decreases in GM volume and cortical thickness 
and with an increase in CSF volume (Table 2), as expected 
from previously published analyses of this cohort [16]. After 
adjusting for age, gender and education years, higher CAIDE 
score remained associated with a decrease in GM volume 
(Table 2). APOE ε4 allele carriership was not a significant 
predictive variable of any tissue volume or cortical thickness 
cross-sectionally or longitudinally.
Voxel‑based morphometry
Cross-sectionally, CAIDE-high subjects showed smaller 
GM volume in the temporal, occipital, and fusiform cor-
tex and lingual gyrus in comparison with CAIDE-low 
subjects at baseline (Fig. 1). Longitudinally, CAIDE-high 
subjects showed greater percentage of GM volume loss 
compared to CAIDE-low subjects in the supramarginal 
gyrus, angular gyrus, precuneus, lateral occipital cortex, 
superior parietal lobule and cingulate gyrus (Fig. 2). VBM 
results with cluster details are shown in Table 3. 76.6% 
Table 1  Baseline characteristics 
of study participants
Plus-minus values are means ± standard deviation. P value represents the P value of statistical difference 
between subjects with CAIDE score > 6 and CAIDE score ≤ 6
APOE apolipoprotein E, BMI body mass index, CAIDE Cardiovascular Risk Factors, Aging, and Dementia 
risk, FHD + with family history of dementia, SBP systolic blood pressure
All subjects CAIDE score > 6 CAIDE score ≤ 6 P value
n 160 68 92
CAIDE score 5.9 ± 2.9 8.5 ± 1.6 4.0 ± 2.0
Age 52.0 ± 5.3 55.0 ± 3.7 49.8 ± 5.3  < 0.001
Female n (%) 114 (71.2) 42 (61.8) 72 (78.3) 0.023
Education years 16.1 ± 3.4 15.3 ± 3.4 16.6 ± 3.3 0.028
APOE ε4 carriers n (%) 61 (38.1) 39 (57.4) 22 (23.9)  < 0.001
SBP (mmHg) 121.6 ± 14.7 127.1 ± 15.3 117.5 ± 12.8  < 0.001
BMI (kg/m2) 27.1 ± 4.7 29.2 ± 5.3 25.6 ± 3.4  < 0.001
Total cholesterol (mmol/L) 5.6 ± 1.0 5.7 ± 1.2 5.5 ± 0.9 0.25
Physical activity (n and % of 
subjects defined as active)
33 (20.6) 11 (16.2) 22 (23.9) 0.23
FHD + n (%) 86 (53.8) 43 (63.2) 43 (46.7) 0.039
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of the regions showing greater percentage of GM volume 
loss in CAIDE-high subjects were located within the AD 
signature cortical regions [25] (Table 4).
Discussion
Following a recent study reporting the association of 
CAIDE score with global GM atrophy and ventricular 
enlargement in the PREVENT-Dementia cohort [16], 
the present study has investigated GM associations with 
Table 2  Results of the linear 
regressions with brain volumes 
and cortical thickness at 
baseline and the percentage 
of  changea over 2 years as 
dependent variables and with 
binary CAIDE score as an 
independent variable
CAIDE Cardiovascular Risk Factors, Aging, and Dementia risk, CSF cerebrospinal fluid, GM grey matter, 
SE standard error, TIV total intracranial volume, WM white matter
a Percentage of change over 2 years was calculated by (measurement at follow-up – measurement at base-
line)/measurement at baseline
b CAIDE score was used as an independent variable with age, gender, and education years added as covari-
ates in linear regressions
c Relative volume was used in analyses, calculated by absolute volume/TIV and represented as a percentage
* Statistically significance defined as P < 0.05
CAIDE score univariate CAIDE score  covariateb
GMc (%)
 Baseline β = − 0.098, SE = 0.030, P = 0.0016* β = − 0.54, SE = 0.36, P = 0.14
 Percentage of change β = − 0.065, SE = 0.021, P = 0.0020* β = − 0.0077, SE = 0.0034, P = 0.026*
Cortical thickness (mm)
 Baseline β = − 0.045, SE = 0.029, P = 0.13 β = − 0.0053, SE = 0.034, P = 0.87
 Percentage of change β = − 0.061, SE = 0.024, P = 0.014* β = − 0.053, SE = 0.029, P = 0.064
CSFc (%)
 Baseline β = 0.064, SE = 0.031, P = 0.042* β = 0.020, SE = 0.036, P = 0.57
 Percentage of change β = 0.071, SE = 0.026, P = 0.0065* β = 0.055, SE = 0.030, P = 0.067
WMc (%)
 Baseline β = − 0.0025, SE = 0.028, P = 0.93 β = 0.016, SE = 0.032, P = 0.62
 Percentage of change β = − 0.033, SE = 0.021, P = 0.13 β = − 0.019, SE = 0.025, P = 0.45
TIV  (cm3)
 Baseline β = 0.055, SE = 0.029, P = 0.059 β = 0.022, SE = 0.027, P = 0.42
 Percentage of change β = 0.012, SE = 0.017, P = 0.48 β = 0.012, SE = 0.020, P = 0.53
Fig. 1  Voxel-based morphometry results of cross-sectional grey mat-
ter (GM) comparison between subjects with Cardiovascular Risk Fac-
tors, Aging, and Dementia risk (CAIDE) score > 6 (n = 68) and sub-
jects with CAIDE score ≤ 6 (n = 92) at baseline. Areas in red-yellow 
represent areas, where the GM volume was lower in subjects with 
CAIDE score > 6 than subjects with CAIDE score ≤ 6 (family-wise 
error corrected P < 0.05), adjusting for age, gender, education years 
and total intracranial volume
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CAIDE score at a voxel-wise level to identify specific 
structures with accelerated GM atrophy. The present study 
has also investigated the association of CAIDE score with 
cortical thickness. Our results for the global tissue vol-
umes are in line with the previous study [16], using in the 
present study a different image processing software tool. 
Using VBM the current study has investigated the voxel-
wise associations between GM volume and CAIDE score 
and has localized specific regions with increased GM loss 
predicted by a baseline CAIDE score greater than 6. We 
have shown that in cognitively healthy middle-aged sub-
jects a CAIDE score greater than 6 was associated with 
Fig. 2  Voxel-based morphometry results of comparison of the grey 
matter (GM) percentage of change over 2 years between subjects with 
Cardiovascular Risk Factors, Aging, and Dementia risk (CAIDE) 
score > 6 (n = 68) and subjects with CAIDE score ≤ 6 (n = 92). Areas 
in red-yellow represent areas, where the percentage of GM loss was 
greater in subjects with CAIDE score > 6 than subjects with CAIDE 
score ≤ 6 (family-wise error corrected P < 0.05), adjusting for age, 
gender, education years and total intracranial volume
Table 3  VBM results of GM 
volume comparison between 
subjects with CAIDE score > 6 
and subjects with CAIDE 
score ≤ 6
CAIDE Cardiovascular Risk Factors, Aging, and Dementia risk, FWE family-wise error, GM grey matter, 
MNI Montreal Neurological Institute, VBM voxel-based morphometry






Temporal, occipital and fusiform cortex; 
Lingual gyrus
39 − 24 − 54 − 10.5 0.047
Longitudinal
Supramarginal gyrus; Angular gyrus 4109 51 − 42 34.5 0.020
Precuneus 2270 15 − 57 25.5 0.031
Lateral occipital cortex 342 43.5 − 79.5 − 1.5 0.038
Superior parietal lobule 92 − 25.5 − 54 49.5 0.039
Cingulate gyrus 46 3 − 37.5 33 0.049
Table 4  Cluster sizes of AD 
signature cortical  regionsa, 
regions showing increased GM 
atrophy in subjects with CAIDE 
score > 6, and their overlapped 
regions
AD Alzheimer’s disease, CAIDE Cardiovascular Risk Factors, Aging, and Dementia risk, GM grey matter
a AD signature cortical regions include eight main regions (inferior temporal gyrus, temporal pole, angular 
gyrus, superior frontal gyrus, superior parietal lobule, supramarginal gyrus, precuneus, inferior frontal sul-
cus)[25]
Anatomical region Cluster size (voxels)
AD signature cortical regions 101,020
Regions with increased GM atrophy in subjects with CAIDE score > 6 6859
AD signature cortical regions with increased GM atrophy in subjects with CAIDE 
score > 6
5255
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lower GM volume in the temporal, occipital, and fusiform 
cortex and lingual gyrus cross-sectionally and with accel-
erated GM atrophy longitudinally in the supramarginal 
gyrus, angular gyrus, precuneus, lateral occipital cortex, 
superior parietal lobule and cingulate gyrus. These results 
were adjusted for the effects of age, gender, education and 
TIV.
The structures demonstrating accelerated atrophy with a 
high CAIDE score are involved in the process of conscious-
ness, integration of elements, visual-spatial memory, and 
episodic memory according to the literature [26–29]. The 
majority of these regions could be classified as “AD signa-
ture cortical regions”, where AD-related cortical thinning 
often occurs [25] and such thinning has been suggested to 
be related to greater likelihood of progression from mild 
cognitive impairment to mild AD [30] and related to symp-
tom severity in mild AD [25]. Based on findings from the 
present study, some of these AD signature cortical regions 
are vulnerable to accelerated GM atrophy associated with a 
high CAIDE score in midlife. In previous studies, CAIDE 
score has been more commonly examined as a continuous 
variable [11, 15, 31, 32]. A longitudinal study on a Finnish 
population has shown that increased midlife CAIDE score 
was associated with lower total GM volume and lower AD 
signature cortical thickness [11]. We have also examined 
the association between CAIDE score and cortical thick-
ness in this present study and found that a CAIDE score > 6 
was associated with increased cortical thinning although the 
association did not survive after adding age, gender and edu-
cation years as covariates. The Finnish study has also found 
that higher midlife CAIDE score was associated with lower 
hippocampal volume, more pronounced deep WM lesions, 
more pronounced visually rated medial temporal atrophy 
(MTA) and poorer cognition later in life [11]. Higher midlife 
CAIDE score has been found to be associated with more 
severe MTA up to 30 years later also in another Finnish 
study [31] and in a cross-sectional study of non-demented 
subjects in Sweden [32]. We have found in this present study 
that higher CAIDE score was associated with accelerated 
GM atrophy in approximately 5% of the AD signature corti-
cal regions [25] but not the medial temporal lobe. The pos-
sible reason for the discrepancy might be that the previous 
longitudinal studies mentioned above followed subjects for 
an average of more than 15 years, while this present study 
was based on longitudinal analyses over only 2 years. In the 
long run MTA might be associated with high midlife CAIDE 
score but short-term changes associated with high CAIDE 
score in midlife might be mostly concentrated in regions 
shown in this present study. Increased atrophy in these 
regions might, therefore, suggest an increased vulnerability 
to AD indicated by higher CAIDE score during midlife. The 
present results also suggest that CAIDE score might be a 
sensitive score to assist in detecting potentially AD-related 
brain structural alternations in cognitively healthy middle-
aged subjects.
CAIDE score was calculated based on age, gender and 
education in addition to vascular risk factors and APOE 
genotype. Since age has been suggested to be the largest 
contributor to the dementia risk predictive effect of CAIDE 
score [33], this present study, in addition to analyzing 
CAIDE score as a single independent variable, also ana-
lyzed CAIDE score with age, gender and education years as 
covariates to control for any linear effects of these factors. 
The voxel-wise association between CAIDE score and GM 
atrophy remained significant after controlling for the effects 
of age, gender, and education years. In addition, APOE 
genotype in this cohort was not associated with GM volume 
loss over time. Hence, the association between CAIDE score 
and GM atrophy observed in VBM analyses might be mostly 
driven by vascular factors within the CAIDE score. This 
is of particular importance considering that around a third 
of AD cases worldwide might be attributable to potentially 
modifiable risk factors, including some risk factors that are 
taken into account when calculating the CAIDE score, such 
as midlife hypertension, midlife obesity, physical inactivity, 
and low education [10]. The increased GM loss in middle-
aged subjects with a higher dementia risk score suggests 
that the observed accelerated GM atrophy in several AD-
signature regions might potentially be delayed by improving 
modifiable vascular risk factors.
Although baseline volume differences were found 
between CAIDE-high and CAIDE-low subjects in a very 
small number of areas, these areas did not show differential 
degree of atrophy over time between the groups. This possi-
bly suggests that the baseline differences found in this study 
had been established in the previous years of life and the rate 
of atrophy in these areas during midlife might not be sig-
nificantly associated with the risk of dementia as defined by 
CAIDE score. Given that only a very small number of areas 
showed subtle baseline differences, the differences could 
also be attributable to inherited volume differences between 
individuals, and therefore, it is reasonable that some regions 
showing baseline differences are generally unaffected in AD. 
On the other hand, it is important to indicate that the cortical 
regions with differences in longitudinal GM atrophy between 
groups did not show any difference at baseline. One possible 
explanation is that these subjects might be at the age when 
AD signature cortical regions are just beginning to show 
accelerated atrophy associated with a higher risk of dementia 
as predicted by CAIDE score, suggesting that possible inter-
ventions should be implemented at this age or even earlier.
Strengths of this study include its longitudinal design. 
The longitudinal image preprocessing stream in CAT12 
used in this study was developed and optimized to detect 
more subtle effects over shorter periods in comparison with 
traditional cross-sectional preprocessing pipelines and, 
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therefore, conferred an advantage in this middle-aged and 
cognitively healthy population, in which any differences 
related to dementia risk might be more subtle than those 
normally observed in older age over longer periods of time. 
CAT12 pipeline is also considered an advanced but compu-
tationally less expensive tool in brain volume segmentation 
[34]. A second strength is that CAIDE score was originally 
developed in middle-aged subjects, and therefore, it is the 
most appropriate and sensitive for use in assessments of 
middle-aged people. Finally, age, gender and education years 
were adjusted in VBM analyses, and therefore, the increased 
atrophy associated with high CAIDE score should mainly 
indicate the impact of vascular factors.
A limitation of this study is that the actual future inci-
dence of dementia in these subjects remains unknown 
and requires long-term follow-up to reveal the association 
between CAIDE score, brain atrophy and cognitive decline 
to a dementia syndrome. Additionally, it should be noted that 
subjects in the PREVENT-Dementia cohort were all vol-
unteering participants. They might not perfectly reflect the 
general population, as they were likely to be more concerned 
about their general health and have been more proactively 
reducing modifiable risk factors for dementia.
Conclusion
To our knowledge, this is the first longitudinal study to dem-
onstrate accelerated GM atrophy concentrated in the supra-
marginal gyrus, angular gyrus, precuneus, lateral occipital 
cortex, superior parietal lobule and cingulate gyrus at middle 
age associated with high CAIDE score. These findings high-
light the possibility and significance of early AD interven-
tion through modifiable midlife vascular risk factors. AD 
diagnosis and interventions should be implemented early 
before symptoms occur. Interventions could, in light of 
present findings of subtle longitudinal GM volume changes 
occurring in midlife, possibly be informed by CAIDE score 
and implemented during or even earlier than middle age. 
Planned longitudinal analysis of the whole PREVENT-
Dementia cohort (target recruitment: 700 people) to con-
firm the specific structures of accelerated atrophy associated 
with high CAIDE score in midlife and long-term follow-up 
to investigate the impact on clinical cognitive performance 
would be valuable. Further investigation into the specific 
midlife vascular risk factors accelerating GM loss in these 
regions would be important for the potential development of 
disease prevention and early intervention strategies.
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